Rallybio (RLYB) News Today $0.95 -0.03 (-2.68%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Promising Preclinical Data and Clinical Advancements Justify Buy Rating for RallybioDecember 11, 2024 | markets.businessinsider.comRallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual MeetingDecember 10, 2024 | businesswire.comRallybio price target lowered to $7 from $8 at JMP SecuritiesDecember 6, 2024 | markets.businessinsider.comRallybio’s RLYB116 Program Developments and Financial Stability Support Buy RatingDecember 5, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Rallybio (RLYB)December 5, 2024 | markets.businessinsider.comRallybio’s RLYB116: Promising Developments and Buy Rating Driven by Enhanced Manufacturing and Potential in Phase 1 TrialsDecember 4, 2024 | markets.businessinsider.comRallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025December 2, 2024 | finance.yahoo.comRallybio Flat on Release of New FindingsNovember 27, 2024 | baystreet.caRallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant WomenNovember 27, 2024 | businesswire.comRallybio to Present at the 2024 Evercore ISI HealthCONx ConferenceNovember 26, 2024 | finance.yahoo.comRallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 InhibitorNovember 25, 2024 | finance.yahoo.comRallybio’s Promising Advances and Financial Projections Earn ‘Buy’ Rating from AnalystNovember 22, 2024 | markets.businessinsider.comRallybio announces initiation of Phase 2 clinical trial of RLYB212November 22, 2024 | markets.businessinsider.comRallybio Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 8, 2024 | finance.yahoo.comRallybio’s Strategic Clinical Advancements and Financial Stability Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comTwo former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotechNovember 6, 2024 | finance.yahoo.comRallybio’s trial applications of RLYB212 in pregnant women with FNAIT approvedOctober 30, 2024 | markets.businessinsider.comRallybio (NASDAQ:RLYB) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comRallybio shares hold Buy rating on HPP treatment dataOctober 3, 2024 | investing.comBuy Rating on Rallybio Amidst Promising Developments in HPP Treatment and Potential Market DisruptionOctober 2, 2024 | markets.businessinsider.comRallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual MeetingSeptember 23, 2024 | businesswire.comFierce Names Rallybio to the 2024 Fierce 50 List as an Innovation HonoreeSeptember 9, 2024 | finance.yahoo.comBuy Rating on Rallybio Stock Fueled by Promising RLYB212 Trial Outcomes and Potential FNAIT Treatment BreakthroughSeptember 4, 2024 | markets.businessinsider.comBuy Rating on Rallybio: Promising RLYB212 Developments Signal Strong Market PotentialAugust 30, 2024 | markets.businessinsider.comRallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and HaemostasisAugust 29, 2024 | finance.yahoo.comNational Vision Releases 2023 Sustainability ReportAugust 27, 2024 | businesswire.comRallybio to Present at Upcoming Investor ConferencesAugust 27, 2024 | businesswire.comRallybio Corporation (RLYB) Stock Historical Prices & Data - Yahoo FinanceAugust 10, 2024 | ca.finance.yahoo.comIs Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?August 10, 2024 | finance.yahoo.comRLYB Stock Earnings: Rallybio Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comRallybio’s RLYB212 Shows Promise: Buy Rating Affirmed Amid Positive Trial and Market PotentialAugust 9, 2024 | markets.businessinsider.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | 247wallst.comRallybio Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 8, 2024 | stockhouse.comRallybio Co. (NASDAQ:RLYB) Receives Average Rating of "Moderate Buy" from AnalystsShares of Rallybio Co. (NASDAQ:RLYB - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendJuly 31, 2024 | marketbeat.comRallybio Co. (NASDAQ:RLYB) Sees Large Drop in Short InterestRallybio Co. (NASDAQ:RLYB - Get Free Report) was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 606,900 shares, a decline of 57.6% from the June 30th total of 1,430,000 shares. Based on an average daily trading volume, of 243,900 shares, the short-interest ratio is presently 2.5 days. Approximately 2.6% of the shares of the stock are short sold.July 29, 2024 | marketbeat.comRallybio Co. (NASDAQ:RLYB) Given Average Recommendation of "Moderate Buy" by AnalystsRallybio Co. (NASDAQ:RLYB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy raJuly 6, 2024 | marketbeat.comRallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsJune 17, 2024 | businesswire.comRallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Rallybio Co. (NASDAQ:RLYB - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendatioJune 11, 2024 | marketbeat.comRallybio (NASDAQ:RLYB) Trading Down 0.7%Rallybio (NASDAQ:RLYB) Shares Down 0.7%June 8, 2024 | marketbeat.com3 Sorry Biotech Stocks to Sell in May While You Still CanMay 31, 2024 | investorplace.comRallybio Co. (NASDAQ:RLYB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRallybio Co. (NASDAQ:RLYB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year targMay 17, 2024 | marketbeat.comJP Morgan Downgrades Rallybio (RLYB)May 16, 2024 | msn.comRallybio (NASDAQ:RLYB) Rating Lowered to Neutral at JPMorgan Chase & Co.JPMorgan Chase & Co. lowered shares of Rallybio from an "overweight" rating to a "neutral" rating in a research report on Wednesday.May 15, 2024 | marketbeat.comBuy Rating Affirmed for Rallybio: Promising FNAIT Drug Candidate and Strong FinancialsMay 10, 2024 | markets.businessinsider.comRallybio (NASDAQ:RLYB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Rallybio in a report on Friday.May 10, 2024 | marketbeat.comRallybio’s Advancements and Financial Health Prompt a Buy Rating from Analyst Jonathan WollebenMay 10, 2024 | markets.businessinsider.comRallybio Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 9, 2024 | finance.yahoo.comRallybio to Present at the 2024 Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comabrdn plc Takes $4.13 Million Position in Rallybio Co. (NASDAQ:RLYB)abrdn plc purchased a new position in Rallybio Co. (NASDAQ:RLYB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,727,067 shares of the company's stock, valued at approximately $4,128,000. abrdnApril 29, 2024 | marketbeat.comShort Interest in Rallybio Co. (NASDAQ:RLYB) Increases By 126.0%Rallybio Co. (NASDAQ:RLYB - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 2,960,000 shares, an increase of 126.0% from the March 31st total of 1,310,000 shares. Approximately 17.2% of the company's stock are sold short. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is presently 1.9 days.April 28, 2024 | marketbeat.com Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover RLYB Media Mentions By Week RLYB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLYB News Sentiment▼0.000.60▲Average Medical News Sentiment RLYB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLYB Articles This Week▼01▲RLYB Articles Average Week Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 2seventy bio News Checkpoint Therapeutics News Nkarta News Zura Bio News Cidara Therapeutics News Ventyx Biosciences News scPharmaceuticals News TScan Therapeutics News Nanobiotix News FitLife Brands News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLYB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
